
A recent study emphasizes the limited effectiveness of current serum tumor markers, such as α-fetoprotein, human chorionic gonadotrophin, and lactate dehydrogenase, in detecting testicular cancer relapse. False-positive elevations in follow-up monitoring are frequent, while some patients with proven relapse do not show elevated levels. The study suggests that circulating microRNAs could serve as better biomarkers for relapse detection. These findings highlight the potential of utilizing microRNAs as improved indicators for identifying testicular cancer relapse.
Like
Save
Share